Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVillemagne, Victor Len
dc.contributor.authorOng, Kevinen
dc.contributor.authorMulligan, Rachel Sen
dc.contributor.authorHoll, Gerharden
dc.contributor.authorPejoska, Svetlanaen
dc.contributor.authorJones, Garethen
dc.contributor.authorO'Keefe, Graeme Jen
dc.contributor.authorAckerman, Uween
dc.contributor.authorTochon-Danguy, Henrien
dc.contributor.authorChan, J Gordonen
dc.contributor.authorReininger, Cornelia Ben
dc.contributor.authorFels, Luederen
dc.contributor.authorPutz, Barbaraen
dc.contributor.authorRohde, Beateen
dc.contributor.authorMasters, Colin Len
dc.contributor.authorRowe, Christopher Cen
dc.identifier.citationJournal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 2011; 52(8): 1210-7en
dc.description.abstractAmyloid imaging with (18)F-labeled radiotracers will allow widespread use, facilitating research, diagnosis, and therapeutic development for Alzheimer disease. The purpose of the study program was to compare cortical amyloid deposition using (18)F-florbetaben and PET in controls and subjects with mild cognitive impairment (MCI), frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies (DLB), vascular dementia (VaD), Parkinson disease (PD), and Alzheimer disease (AD).One hundred nine subjects in 3 clinical studies at Austin Health were reviewed: 32 controls, 20 subjects with MCI, and 30 patients with AD, 11 with FTLD, 7 with DLB, 5 with PD, and 4 with VaD underwent PET after intravenous injection of 300 MBq of (18)F-florbetaben. Standardized uptake value ratios (SUVR) using the cerebellar cortex as a reference region were calculated between 90 and 110 min after injection.When compared with the other groups, AD patients demonstrated significantly higher SUVRs (P < 0.0001) in neocortical areas. Most AD patients (96%) and 60% of MCI subjects showed diffuse cortical (18)F-florbetaben retention. In contrast, only 9% of FTLD, 25% of VaD, 29% of DLB, and no PD patients and 16% of controls showed cortical binding. Although there was a correlation between Mini Mental State Examination and β-amyloid burden in the MCI group, no correlation was observed in controls, FTLD or AD.(18)F-florbetaben had high sensitivity for AD, clearly distinguished patients with FTLD from AD, and provided results comparable to those reported with (11)C-Pittsburgh Compound B in a variety of neurodegenerative diseases.en
dc.subject.otherAged, 80 and overen
dc.subject.otherAlzheimer Disease.radionuclide imagingen
dc.subject.otherAmyloid beta-Peptides.metabolismen
dc.subject.otherAniline Compounds.pharmacologyen
dc.subject.otherCase-Control Studiesen
dc.subject.otherCerebellum.radionuclide imagingen
dc.subject.otherDementia.radionuclide imagingen
dc.subject.otherFluorine Radioisotopes.pharmacologyen
dc.subject.otherFrontotemporal Dementia.radionuclide imagingen
dc.subject.otherImage Processing, Computer-Assisteden
dc.subject.otherLewy Bodies.radionuclide imagingen
dc.subject.otherMiddle Ageden
dc.subject.otherNeurodegenerative Diseases.radionuclide imagingen
dc.subject.otherPositron-Emission Tomography.methodsen
dc.subject.otherTreatment Outcomeen
dc.titleAmyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Nuclear Medicineen
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australiaen
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.